These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 28666800

  • 1. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
    Yuan Z, Li D, Feng P, Xue G, Ji C, Li G, Hölscher C.
    Eur J Pharmacol; 2017 Oct 05; 812():82-90. PubMed ID: 28666800
    [Abstract] [Full Text] [Related]

  • 2. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
    Feng P, Zhang X, Li D, Ji C, Yuan Z, Wang R, Xue G, Li G, Hölscher C.
    Neuropharmacology; 2018 May 01; 133():385-394. PubMed ID: 29462693
    [Abstract] [Full Text] [Related]

  • 3. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
    Ji C, Xue GF, Lijun C, Feng P, Li D, Li L, Li G, Hölscher C.
    Brain Res; 2016 Mar 01; 1634():1-11. PubMed ID: 26453833
    [Abstract] [Full Text] [Related]

  • 4. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
    Zhang L, Zhang L, Li Y, Li L, Melchiorsen JU, Rosenkilde M, Hölscher C.
    J Parkinsons Dis; 2020 Mar 01; 10(2):523-542. PubMed ID: 31958096
    [Abstract] [Full Text] [Related]

  • 5. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
    Cao L, Li D, Feng P, Li L, Xue GF, Li G, Hölscher C.
    Neuroreport; 2016 Apr 13; 27(6):384-91. PubMed ID: 26918675
    [Abstract] [Full Text] [Related]

  • 6. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
    Jalewa J, Sharma MK, Gengler S, Hölscher C.
    Neuropharmacology; 2017 May 01; 117():238-248. PubMed ID: 28223210
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model.
    Zhang L, Zhang L, Li L, Hölscher C.
    Neuropeptides; 2018 Oct 01; 71():70-80. PubMed ID: 30017231
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
    Hölscher C.
    Neuropharmacology; 2018 Jul 01; 136(Pt B):251-259. PubMed ID: 29402504
    [Abstract] [Full Text] [Related]

  • 14. Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model.
    Li Y, Liu W, Li L, Hölscher C.
    Neuropharmacology; 2016 Feb 01; 101():255-63. PubMed ID: 26453962
    [Abstract] [Full Text] [Related]

  • 15. The novel GLP-1/GIP dual receptor agonist DA3-CH is neuroprotective in the pilocarpine-induced epileptogenesis rat model.
    Tian MJ, Wang RF, Hölscher C, Mi RL, Yuan ZY, Li DF, Xue GF.
    Epilepsy Res; 2019 Aug 01; 154():97-106. PubMed ID: 31121474
    [Abstract] [Full Text] [Related]

  • 16. Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model.
    Zhang Y, Chen Y, Li L, Hölscher C.
    Behav Brain Res; 2015 Oct 15; 293():107-13. PubMed ID: 26187689
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ, Tenenbaum A.
    Cardiovasc Diabetol; 2021 Nov 24; 20(1):225. PubMed ID: 34819089
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease.
    Yang X, Feng P, Ji R, Ren Y, Wei W, Hölscher C.
    Expert Opin Ther Targets; 2022 May 24; 26(5):445-460. PubMed ID: 35584372
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.